The non-core business of this divestiture is Takeda's product portfolio in cardiovascular and metabolic fields sold in Chinese mainland. In fiscal year 20 19, the net sales of these products reached nearly1950,000 US dollars, and the main sales contribution came from cardiovascular products such as anthocyanins. These products play an important role in meeting the medical needs of patients in China, but they do not belong to Takeda's core business areas: digestion, rare diseases, blood products, cancer and neuroscience-these core areas will promote Takeda's long-term performance growth.
Ricardo Marek, President of Takeda's Growth and Emerging Markets Division, said: "The China market is very important for Takeda, and we will accelerate the provision of innovative drugs for China patients with complex and rare diseases. This divestiture will enable us to focus more on core areas and invest resources to accelerate the introduction of more highly innovative drugs into China and other emerging markets. "
Costa Saroukos, chief financial officer of Takeda, further pointed out that Takeda will continue to increase the China market, and more than 65,438+05 innovative drugs will be listed in the next five years. "By continuing to implement the goal of financial stability, including debt repayment and focusing on highly innovative products, we can maintain sustained business growth and bring innovative drugs and treatments that change lives to patients around the world."
It is understood that Takeda plans to continue to repay the debt through the business divestiture income from fiscal year 2002/KLOC-0 to fiscal year 2023, accelerate the deleveraging process, and achieve the goal of doubling the net debt/adjusted income before interest and tax.
The debt mentioned by Takeda Pharmaceutical actually comes from the previous acquisition of rare disease pharmaceutical companies.
20 19, 1, announced the completion of the acquisition of Charles for $62 billion, making Takeda one of the top ten pharmaceutical companies in the world. But at the same time, it also faces financial challenges. In fact, in the process of acquisition, it was questioned by minority shareholders because of the debt problem.
At that time, Christophe Weber, CEO of Takeda Pharmaceutical, said that the transaction would be profitable due to the planned cost reduction, and predicted that at least $654.38+04 billion would be saved each year in the next three years after the transaction was completed. At the same time, Takeda Pharmaceutical also plans to sell non-core assets as high as $654.38+0 billion to help the Group repay its loans. Andy Plenter, director of global R&D of Takeda Pharmaceutical, also said: "We have a divestiture plan that will enable us to reach the level stipulated by credit institutions within three to five years. Our credit rating may be downgraded by one level, but it is still higher than the rating of junk bonds, which is very important for us. " According to the financial report, as of the end of 20 19, Takeda's interest-bearing debt was $46 billion.
Takeda said that in 2020, Takeda will continue to promote the global strategy of business divestiture and accelerate the transformation, and has completed the goal of divesting non-core business of more than 654.38 billion US dollars. Since 20 19 and 1, takeda has announced 10 business divestitures worldwide, with a total amount of about11300 million USD. These divestitures mainly include:
It is announced that Takeda's consumer health care business will be divested to Oscar A-Co KK Company, which is controlled by American private equity giant Blackstone Group, for about 242 billion yen (US$ 2.3 billion).
Accumulated nearly $2 billion, and divested the non-core business of growth and emerging markets to four buyers.
Stripped off some over-the-counter drugs and non-core businesses in Europe and sold them to Orifarm for $700 million. Split the non-core business in Europe and Canada to the American company Cheplapharm for about $562 million.
Peel off TachoSil fibrin glue and give Corza Health about 500 million euros.
The non-core business of this divestiture is Takeda's product portfolio in cardiovascular and metabolic fields sold in Chinese mainland, which is said to include products such as Bilos, Yaningding and Aiketo.
Because of the quantity purchasing policy, cardiovascular, endocrine and antibiotic products have become the "optimization" targets of foreign companies. In addition to Takeda, Pfizer also divested its cardiovascular product line to Puqiang, and Novartis related product lines are also constantly merging. The future adjustment will continue, and more and more foreign companies will adjust their non-core businesses.
It is reported that the purpose of Takeda Pharmaceutical's divestiture of non-core assets this time is to concentrate resources on its innovative drug product portfolio and promote the company's long-term growth by developing new products in the fields of gastrointestinal diseases (GI), rare diseases and hematological diseases. It is planned to achieve the goal of 15 new drugs being approved for marketing within five years.
In the news that Takeda Pharmaceutical divested its non-core business in China, another episode appeared. Because of a translation error, it was once reported that Cornerstone became the buyer of Takeda Pharmaceutical.
But it's really Heisen. According to the agreement between the two parties, Haisen will exclusively own the rights, ownership and interests of these products in Chinese mainland. At present, employees who are directly affiliated to Chinese mainland Internal Medicine Division and are responsible for these products will be transferred to Haisen. In addition, Takeda also signed a production and supply agreement with Haisen, and will continue to supply these products for Haisen.
265438+20 th Century Business Herald reporter found that Haisen Co., Ltd. was established on September 6, 2020 with a registered capital of 50 million yuan, and Ruimu Investment holds 100%, and Heji is its senior manager. Ruimu Investment was established on 20 19 12 3 1, with legal representative Yang and registered capital of 5 million yuan.
The shareholders of Ruimu Investment are 30% and 25%, Hefu Ruimu Consulting Management Center (Limited Partnership) (hereinafter referred to as Ruimu) and Yang 20%.
With further penetration of equity, the shareholder of Ramu is Anhui Hexi Industrial Park Operation Management Co., Ltd. (legal representative Ji holds shares 100%).
In Wutian Pharmaceutical official website, Haisen was introduced as an innovative biomedical science and technology enterprise funded by Feidong County of Hefei City and invested by Anhui Ruim Investment Management Co., Ltd.
According to the official website Feidong County, since the beginning of this year, Feidong County has firmly established the consciousness of "grasping projects means grasping development", made high-level planning and high-standard deployment, seized the opportunity of integrated development in the Yangtze River Delta, carried out accurate investment promotion around emerging industries such as artificial intelligence, high-end equipment manufacturing and biomedicine, and made every effort to grasp projects, stabilize investment and promote growth.1-kloc-0/65438
For more information, please download 2 1 financial APP.